-+ 0.00%
-+ 0.00%
-+ 0.00%
Pharmgen Science Scraps Production Expansion Plan
Share
Listen to the news
Pharmgen Science Scraps Production Expansion Plan
  • Pharmgen Science's board resolved on November 17, 2026, to abandon its production expansion plan at Osong Biopolis Industrial Complex.
  • Changed investment conditions weakened expected profitability, raising concerns that proceeding could harm shareholder value.
  • The board also authorized a sale application for the 14,266.6-square-meter industrial site in Cheongju through a public sale process.
  • The expansion investment agreement, disclosed on November 22, 2022, was nonbinding.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmgen Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261117800423), on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending